


**Product Name** : T-025  
**Cat. No.** : PC-35047  
**CAS No.** : 2407433-00-3  
**Molecular Formula** : C<sub>21</sub>H<sub>18</sub>N<sub>8</sub>  
**Molecular Weight** : 382.431  
**Target** : Cdc2-like Kinase (CLK)  
**Solubility** : 10 mM in DMSO



## Biological Activity

T-025 (T025, CLK inhibitor T-025) is an orally available, potent inhibitor of **Cdc2-like kinases (CLKs)** with K<sub>d</sub> of 4.8, 0.096, 6.5, and 0.61 nM for CLK1, CLK2, CLK3, and CLK4, also inhibits **DYRK1A** and **DYRK1B** with IC<sub>50</sub> of 0.074 and 1.5 nM. T-025 (T025, CLK inhibitor T-025) reduces CLK-dependent phosphorylation, induces skipping exon, resulting in anti-proliferative effect in MDA-MB-468 in vitro and in vivo accompanied by the modulation of pre-mRNA splicing. T-025 (T025, CLK inhibitor T-025) shows sensitivity against high CLK2 expression or MYC amplification cancer cells. T-025 (T025, CLK inhibitor T-025) exhibits significant anti-tumor efficacy in MYC-driven breast tumor allograft models.

## References

Iwai K, et al. *EMBO Mol Med.* 2018 May 16. pii: e8289.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com